Clinical trials: Immunomodulation
Type 1 Diabetes Mellitus
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin.
- Trial name
- DIA-AID2 (NCT01103284)
- Testing
- DiaPep277
- Where
- 75 sites in United States, Austria and 12 more
- Volunteers
- 475 people
- Sponsor
- Andromeda Biotech Ltd.
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting
- Trial name
- NCT00574223
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cytos Biotechnology AG
Heart Transplant, Immunosuppression
HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
This is an unblinded, randomized, controlled, two-arm interventional research study enrolling patients who are undergoing heart transplantation.
- Conditions
- Heart Transplant, Immunosuppression, Allograft
- Trial name
- MOSAIC (NCT05459181)
- Testing
- HeartCare
- Volunteers
- 930 people
- Sponsor
- CareDx
Type 1 Diabetes
Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
The study is an open-label extension study, offering patients who participated and completed previous study 901 to continue treatment with DiaPep277 and clinical follow-up, for 2 additional years.
- Trial name
- NCT00644501
- Testing
- DiaPep277
- Where
- 3 sites in Israel
- Volunteers
- 43 people
- Sponsor
- Andromeda Biotech Ltd.
Immunomodulation
Investigation of a Polyphenol-rich Preparation as Support for Oncology Patients Undergoing Gastrointestinal Tumor Resection
The aim of the study is to demonstrate, under clinical conditions, the effectiveness of the standard product 'Nutridrink' enriched with a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting the…
- Trial name
- NCT06017661
- Testing
- Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds, Nutridrink Skin Repair
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- AronPharma Sp. z o. o.
Chronic Rhinosinusitis (CRS), Exacerbations
Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis
The goal of this clinical research is to learn if Imunoglukan P4H® as an add-on therapy to the standard of care treatment according to the EPOS guidelines (intranasal corticosteroids and saline irrigation) can help to prevent CRS…
- Conditions
- Chronic Rhinosinusitis (CRS), Exacerbations, Respiratory Tract Infections (RTI), Antibiotic Prophylaxis
- Trial name
- EPCCOR (NCT07460934)
- Testing
- Imunoglukan P4H® capsules
- Where
- 5 sites in Czechia, Slovakia
- Volunteers
- 85 people
- Sponsor
- Pleuran, s.r.o.
Perennial Allergy to House Dust Mite and/or Cat
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.
- Trial name
- NCT00575003
- Testing
- CYT003-QbG10
- Where
- 7 sites in Estonia, Latvia and 1 more
- Volunteers
- 64 people
- Sponsor
- Cytos Biotechnology AG
CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced…
- Conditions
- CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
- Trial name
- PILOT (NCT01671774)
- Testing
- IMAB362, Zoledronic acid, Interleukin-2 (1 million IU)
- Where
- 9 sites in Germany, Latvia
- Volunteers
- 29 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Ulcerative Colitis
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response…
- Trial name
- NCT02426372
- Testing
- QBECO SSI
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Qu Biologics Inc.
Type 1 Diabetes
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that causes a deficit of pancreatic islet beta cells. Millions of individuals worldwide have T1D, and incidence increases annually.
- Trial name
- NCT04011020
- Testing
- Stem Cell Educator therapy
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Throne Biotechnologies Inc.
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19
Currently, the growing epidemic of a new coronavirus infectious disease (Covid-19) is wreaking havoc worldwide, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04299152
- Testing
- Stem Cell Educator-Treated Mononuclear Cells Apheresis
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Gastrointestinal Health, Respiratory Health
Clinical Study to Evaluate the Safety and Efficacy of New Probiotic Strains in Health Adults
This trial is to determine the safety of 4 new probiotic strains and to assess their efficacy in reducing the incidence and/or duration of gastrointestinal problems and infections as well as respiratory infections in healthy…
- Conditions
- Gastrointestinal Health, Respiratory Health, Safety
- Trial name
- NCT04758845
- Testing
- Cocktail, CGI314, CSI08
- Where
- Slovenia
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Deerland Enzymes
COVID-19 Infection
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
- Trial name
- NCT04374032
- Testing
- metenkefalin + tridecactide, The standard of care
- Where
- 5 sites in Bosnia and Herzegovina
- Volunteers
- 120 people
- Sponsor
- Bosnalijek D.D
Infertility
Endometrium Immunomodulation by in Utero Administration of Peripheral Blood Mononuclear Cells
One of the most limiting factors in the field of assisted reproduction is implantation failure. A new approach to increase the chances of success involves the use of cells from the patient's blood, peripheral blood mononuclear…
- Trial name
- NCT04648566
- Testing
- Intrauterine administration of hCG-activated peripheral blood mononuclear cells, Intrauterine administration of sperm washing medium
- Where
- Canada
- Volunteers
- 423 people
- Sponsor
- Fertilys
Metastatic Colorectal Cancer
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.
- Trial name
- IMPALA (NCT02077868)
- Testing
- Usual Maintenance, MGN1703 treatment
- Where
- 125 sites in Austria, Belgium and 6 more
- Volunteers
- 540 people
- Sponsor
- Mologen AG
Peripheral Arterial Disease, Arterial Occlusive Diseases
SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes
The purpose of this study is to assess the effects of the Celacade™ system in patients with intermittent claudication.
- Conditions
- Peripheral Arterial Disease, Arterial Occlusive Diseases, Intermittent Claudication
- Trial name
- NCT00111826
- Testing
- Celacade™ system
- Volunteers
- 500 people
- Sponsor
- Vasogen
Gastric Cancer
RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.
- Trial name
- NCT01401075
- Testing
- mistletoe extract, doxifluridine
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Abnoba Gmbh
Seasonal Allergic Rhinitis
A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance
The purpose of the study is to determine whether VAK694 when combined with subcutaneous immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal allergic rhinitis.
- Trial name
- NCT01018693
- Testing
- VAK694; Alutard Avanz SQ
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Alopecia Areata
Stem Cell Educator Therapy in Alopecia Areata
Alopecia Areata (AA) is one of the most common T cell-mediated autoimmune diseases, leading to the chronic and relapsing hair loss.
- Trial name
- NCT01673789
- Testing
- Stem Cell Educator
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Throne Biotechnologies Inc.
Primary Immune Thrombocytopenia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons.
- Trial name
- NCT05422365
- Testing
- Intravenous immunoglobulin (IVIG), 10% solution for infusion
- Where
- 12 sites in Ukraine
- Volunteers
- 32 people
- Sponsor
- Biopharma Plasma LLC